BMX BioMaxima S.A.

2.078USD8.360 PLN · GPW-1.42%Mkt Cap: 8.71M USDP/E: 39.81

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and medi…

Key Statistics

Company
Market Cap8.71M USD
Enterprise Value12.56M USD
Revenue (TTM)15.07M USD
Gross Profit6.63M USD
Net Income (TTM)26.10K USD
Revenue/Share3.60 USD
Last Price2.078 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees143
CountryPL
SectorHealthcare
IndustryDiagnostics & Research
ISINPLBIOMX00015
Valuation
P/E (Trailing)39.81
P/E (Forward)—
PEG—
EV/EBITDA11.39
EV/Revenue0.83
P/S0.58
P/B0.73
EPS (TTM)0.05 USD
EPS (Forward)—
52W Range
2.0780% of range3.294
52W High3.294 USD
52W Low2.078 USD
Profitability
Gross Margin43.76%
Oper. Margin2.33%
EBITDA Margin7.31%
Profit Margin0.17%
ROE0.22%
ROA0.14%
ROIC0.88%
ROCE1.54%
Growth
Revenue Growth7.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF838.80K USD
CapEx (TTM)248.36K USD
FCF Margin5.00%
FCF Yield8.66%
Net Debt3.85M USD
Net Debt/EBITDA3.49
Net Debt/FCF5.10
Balance Sheet
Debt/Equity0.30
Current Ratio1.52
Quick Ratio0.77
Book Value/Sh2.87 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 16, 2023
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.19M
Float2.26M
Insiders34.41%
Institutions0.05%
Technical
SMA 502.404 (-13.5%)
SMA 2002.624 (-20.8%)
Beta0.33
S&P 52W Chg12.00%
Avg Vol (30d)3.41K
Avg Vol (10d)5.31K
Technical Indicators
RSI (14)10.7
MACD-0.3826
MACD Signal-0.3384
MACD Hist.-0.0442
BB Upper2.523 USD
BB Middle2.251 USD
BB Lower1.979 USD
BB Width24.21%
ATR (14)0.0456 USD
Vol Ratio (20d)3.49x

About BioMaxima (WSE: BMX)

›

BioMaxima (WSE: BMX) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 143 employees.

The shares were at 8.360 PLN on 19 November 2026, down 35.7% over 52 weeks. Its 52-week range is 8.360 PLN to 13.25 PLN, and it trades at the bottom of that range.

At a market capitalisation of 35.05M PLN, it trades at 39.8 times trailing earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.8, a premium of 11% for BMX.

BioMaxima reports return on equity of 0.2%, an operating margin of 2.3% and revenue up 7.0% year over year.

Its debt exceeds its cash by 15.48M PLN, a debt-to-equity ratio of 0.30. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.